Mar. 12 at 11:43 AM
Wells Fargo⬆️
$RYTM's PT to
$143 from
$136 and reiterated at an Overweight rating after its interview w/ 10 KOLs.
$LLY $NVO
Wells Fargo said—We are raising our price target to
$143 (from
$136) on slightly higher rev ests.
We are more confident in IMCIVREE's launch in hypothalamic obesity (HO) and its peak opportunity after speaking with docs who represent the early targets post approval. We conducted 1:1 long form interviews with ten KOLs from specialized academic centers treating HO patients. Collectively, these physicians manage ~260 HO pts, reflecting a high-volume cohort: ~90% manage 10-25 pts each, and 40% practice at pituitary COEs-these will be IMCIVREE's early adopters. In the detailed interviews, we covered topics ranging from IMCIVREE's data, future utilization, time to treatment, pt pops, push & pulls for the launch, and more.
